SEC Form 4 · accession 0001405253-26-000013
Tarsus Pharmaceuticals, Inc. · TARS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey S Farrow
Officer — See Remarks
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 4:17 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001819790
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2026 | M | 27,881 | — | A | 71,197 | D | |
| Common Stock | Jun 16, 2026 | S | 14,396 | $60.95 | D | 56,801 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F4 | — | Jun 15, 2026 | M | 27,881 | D | — | — | Common Stock | 27,881 | 27,882 | D |
Explanation of responses
- F1The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
- F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- F3Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
- F4RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
Remarks
Chief Financial Officer and Chief Strategy Officer